Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Arvinas Holding Company ( (ARVN) ).
On February 10, 2026, Arvinas president, CEO and board chair John Houston, Ph.D., notified the company he would resign from those roles effective February 12, 2026, while remaining on the board and transitioning to a consulting position through March 1, 2027. On February 11, 2026, the board named lead independent director Briggs Morrison, M.D., as chair and appointed long‑time executive Randy Teel, Ph.D., as president, CEO, principal executive officer and director, under an amended employment agreement that sets his compensation, equity grants and detailed severance protections, including enhanced benefits and accelerated vesting in the event of a qualifying termination following a change in control.
The consulting agreement with Dr. Houston provides for a lump‑sum COBRA‑related payment, a cash amount equivalent to his 2025 bonus had he remained CEO, additional hourly fees beyond a baseline level of consulting hours and continued equity vesting. The leadership transition concentrates strategic and operational authority with Dr. Teel, who has held multiple senior roles at Arvinas since 2018, while preserving continuity and access to Dr. Houston’s expertise, a combination that may help stabilize governance and signal longer‑term planning to shareholders and employees.
The most recent analyst rating on (ARVN) stock is a Buy with a $14.50 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
Arvinas’ overall stock score is driven by its strong technical momentum and positive corporate events, which are tempered by financial challenges and valuation concerns. The promising clinical pipeline and strategic collaborations provide a positive outlook, but ongoing financial and operational challenges remain significant.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Arvinas, Inc. is a biopharmaceutical company focused on developing targeted protein degradation therapies. The company operates in the life sciences industry, advancing innovative drug candidates through research, development, and strategic corporate initiatives aimed at addressing unmet medical needs in its chosen therapeutic areas.
Average Trading Volume: 1,303,246
Technical Sentiment Signal: Hold
Current Market Cap: $863.2M
For an in-depth examination of ARVN stock, go to TipRanks’ Overview page.